Lastly, given the significance of the PD-1/PD-L1 pathway as a crucial target in cancer immunotherapy, chemotherapeutic molecules with the ability to downregulate PD-L1 expression in tumour cells hold promise for enhancing the immune response. The gene discussed is CD274; the disease is cancer.